© 1999 American Heart Association, Inc.
Original Contributions |
Mechanism of Block and Identification of the Verapamil Binding Domain to HERG Potassium Channels
From the Section of Cardiology, University of Wisconsin, Madison, Wis.
Correspondence to Craig T. January, Section of Cardiology, Room H6/354 CSC, University of Wisconsin Hospitals and Clinics, 600 Highland Ave, Madison, WI 53792. E-mail ctj{at}medicine.wisc.edu
Abstract—Calcium channel antagonists have diverse effects on cardiac electrophysiology. We studied the effects of verapamil, diltiazem, and nifedipine on HERG K+ channels that encode IKr in native heart cells. In our experiments, verapamil caused high-affinity block of HERG current (IC50=143.0 nmol/L), a value close to those reported for verapamil block of L-type Ca2+ channels, whereas diltiazem weakly blocked HERG current (IC50=17.3 µmol/L), and nifedipine did not block HERG current. Verapamil block of HERG channels was use and frequency dependent, and verapamil unbound from HERG channels at voltages near the normal cardiac cell resting potential or with drug washout. Block of HERG current by verapamil was reduced by lowering pHO, which decreases the proportion of drug in the membrane-permeable neutral form. N-methyl-verapamil, a membrane-impermeable, permanently charged verapamil analogue, blocked HERG channels only when applied intracellularly. Verapamil antagonized dofetilide block of HERG channels, which suggests that they may share a common binding site. The C-type inactivation-deficient mutations, Ser620Thr and Ser631Ala, reduced verapamil block, which is consistent with a role for C-type inactivation in high-affinity drug block, although the Ser620Thr mutation decreased verapamil block 20-fold more than the Ser631Ala mutation. Our findings suggest that verapamil enters the cell membrane in the neutral form to act at a site within the pore accessible from the intracellular side of the cell membrane, possibly involving the serine at position 620. Thus, verapamil shares high-affinity HERG channel blocking properties with other class III antiarrhythmic drugs, and this may contribute to its antiarrhythmic mechanism.
Key Words: Ca2+ antagonist • HERG • rapidly activating delayed K+ channel • antiarrhythmic drug • arrhythmia
This article has been cited by other articles:
 |
|
 |
|
  A. Seoane, P. V. Massey, H. Keen, Z. I. Bashir, and M. W. Brown L-Type Voltage-Dependent Calcium Channel Antagonists Impair Perirhinal Long-Term Recognition Memory and Plasticity Processes J. Neurosci., July 29, 2009; 29(30): 9534 - 9544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Ganapathi, M. Kester, and K. S. Elmslie State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy Am J Physiol Cell Physiol, April 1, 2009; 296(4): C701 - C710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hreiche, P. Morissette, H. Zakrzewski-Jakubiak, and J. Turgeon Gender-related Differences in Drug-induced Prolongation of Cardiac Repolarization in Prepubertal Guinea Pigs Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2009; 14(1): 28 - 37. [Abstract] [PDF]
|
|
|
|
 |
|
 G. C. L. Bett and R. L. Rasmusson Modification of K+ channel-drug interactions by ancillary subunits J. Physiol., February 15, 2008; 586(4): 929 - 950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Thomas, M. J. Killeen, I. S. Gurung, P. Hakim, R. Balasubramaniam, C. A. Goddard, A. A. Grace, and C. L.-H. Huang Mechanisms of ventricular arrhythmogenesis in mice following targeted disruption of KCNE1 modelling long QT syndrome 5 J. Physiol., January 1, 2007; 578(1): 99 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Thomas, I. S. Gurung, M. J. Killeen, P. Hakim, C. A. Goddard, M. P. Mahaut-Smith, W. H. Colledge, A. A. Grace, and C. L.-H. Huang Effects of L-type Ca2+ channel antagonism on ventricular arrhythmogenesis in murine hearts containing a modification in the Scn5a gene modelling human long QT syndrome 3 J. Physiol., January 1, 2007; 578(1): 85 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Couture, J. A. Nash, and J. Turgeon The ATP-Binding Cassette Transporters and Their Implication in Drug Disposition: A Special Look at the Heart. Pharmacol. Rev., June 1, 2006; 58(2): 244 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Guo, H. Gang, and S. Zhang Molecular Determinants of Cocaine Block of Human Ether-a-go-go-Related Gene Potassium Channels J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 865 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zhang Isolation and characterization of IKr in cardiac myocytes by Cs+ permeation Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1038 - H1049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Gintant, Z. Su, R. L. Martin, and B. F. Cox Utility of hERG Assays as Surrogate Markers of Delayed Cardiac Repolarization and QT Safety Toxicol Pathol, January 1, 2006; 34(1): 81 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lin, J. Guo, H. Gang, P. Wojciechowski, J. T. Wigle, and S. Zhang Intracellular K+ Is Required for the Inactivation-Induced High-Affinity Binding of Cisapride to HERG Channels Mol. Pharmacol., September 1, 2005; 68(3): 855 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Milan and C. A. MacRae Animal models for arrhythmias Cardiovasc Res, August 15, 2005; 67(3): 426 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Herrera, A. Mamarbachi, M. Simoes, L. Parent, R. Sauve, Z. Wang, and S. Nattel A Single Residue in the S6 Transmembrane Domain Governs the Differential Flecainide Sensitivity of Voltage-Gated Potassium Channels Mol. Pharmacol., August 1, 2005; 68(2): 305 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Delisle, J. K. Slind, J. A. Kilby, C. L. Anderson, B. D. Anson, R. C. Balijepalli, D. J. Tester, M. J. Ackerman, T. J. Kamp, and C. T. January Intragenic Suppression of Trafficking-Defective KCNH2 Channels Associated with Long QT Syndrome Mol. Pharmacol., July 1, 2005; 68(1): 233 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dorn, F. Hermann, A. Ebneth, H. Bothmann, G. Trube, K. Christensen, and C. Apfel Evaluation of a High-Throughput Fluorescence Assay Method for hERG Potassium Channel Inhibition J Biomol Screen, June 1, 2005; 10(4): 339 - 347. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Bokenes, I. Sjaastad, and O. M. Sejersted Artifactual contractions triggered by field stimulation of cardiomyocytes J Appl Physiol, May 1, 2005; 98(5): 1712 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Sticherling, S. Behrens, W. Kamke, A. Stahn, and M. Zabel Comparison of acute and long-term effects of single-dose amiodarone and verapamil for the treatment of immediate recurrences of atrial fibrillation after transthoracic cardioversion Europace, January 1, 2005; 7(6): 546 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Caballero, R. Gomez, L. Nunez, I. Moreno, J. Tamargo, and E. Delpon Diltiazem inhibits hKv1.5 and Kv4.3 currents at therapeutic concentrations Cardiovasc Res, December 1, 2004; 64(3): 457 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Garcia-Ferreiro, D. Kerschensteiner, F. Major, F. Monje, W. Stuhmer, and L. A. Pardo Mechanism of Block of hEag1 K+ Channels by Imipramine and Astemizole J. Gen. Physiol., September 27, 2004; 124(4): 301 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Roden Drug-Induced Prolongation of the QT Interval N. Engl. J. Med., March 4, 2004; 350(10): 1013 - 1022. [Full Text] [PDF]
|
|
|
|
|
|
J. Kang, X.-L. Chen, H. Wang, J. Ji, W. Reynolds, S. Lim, J. Hendrix, and D. Rampe Cardiac Ion Channel Effects of Tolterodine J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 935 - 940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Antzelevitch, L. Belardinelli, L. Wu, H. Fraser, A. C. Zygmunt, A. Burashnikov, J. M. Di Diego, J. M. Fish, J. M. Cordeiro, R. J. Goodrow Jr, et al. Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S65 - S83. [Abstract] [PDF]
|
|
|
|
|
|
R. Balasubramaniam, A. A Grace, R. C Saumarez, J. I Vandenberg, and C. L-H Huang Electrogram prolongation and nifedipine-suppressible ventricular arrhythmias in mice following targeted disruption of KCNE1 J. Physiol., October 15, 2003; 552(2): 535 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zhang, S. J Kehl, and D. Fedida Modulation of human ether-a-go-go-related K+ (HERG) channel inactivation by Cs+ and K+ J. Physiol., May 1, 2003; 548(3): 691 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Madeja, T. Leicher, P. Friederich, M. A. Punke, W. Haverkamp, U. Musshoff, G. Breithardt, and E.-J. Speckmann Molecular Site of Action of the Antiarrhythmic Drug Propafenone at the Voltage-Operated Potassium Channel Kv2.1 Mol. Pharmacol., March 1, 2003; 63(3): 547 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Hassan, H. Oral, C. Scharf, A. Chugh, F. Pelosi, B. P. Knight, S. A. Strickberger, and F. Morady Rate-dependent effect of verapamil on atrial refractoriness J. Am. Coll. Cardiol., February 5, 2003; 41(3): 446 - 451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Segal, J. P. Hayslett, and G. V. Desir On the natriuretic effect of verapamil: inhibition of ENaC and transepithelial sodium transport Am J Physiol Renal Physiol, October 1, 2002; 283(4): F765 - F770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mbai, S. Rajamani, and C. T January The anti-malarial drug halofantrine and its metabolite N-desbutylhalofantrine block HERG potassium channels Cardiovasc Res, September 1, 2002; 55(4): 799 - 805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Fossa, M. J. DePasquale, D. L. Raunig, M. J. Avery, and D. J. Leishman The Relationship of Clinical QT Prolongation to Outcome in the Conscious Dog Using a Beat-to-Beat QT-RR Interval Assessment J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 828 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ekins, W. J. Crumb, R. D. Sarazan, J. H. Wikel, and S. A. Wrighton Three-Dimensional Quantitative Structure-Activity Relationship for Inhibition of Human Ether-a-Go-Go-Related Gene Potassium Channel J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 427 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lecchi, E. Redaelli, B. Rosati, G. Gurrola, T. Florio, O. Crociani, G. Curia, R. R. Cassulini, A. Masi, A. Arcangeli, et al. Isolation of a Long-Lasting eag-Related Gene-Type K+ Current in MMQ Lactotrophs and Its Accommodating Role during Slow Firing and Prolactin Release J. Neurosci., May 1, 2002; 22(9): 3414 - 3425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Thomas, B. Gut, G. Wendt-Nordahl, and J. Kiehn The Antidepressant Drug Fluoxetine Is an Inhibitor of Human Ether-A-Go-Go-Related Gene (HERG) Potassium Channels J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 543 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Eckardt, G. Breithardt, and W. Haverkamp Electrophysiologic Characterization of the Antipsychotic Drug Sertindole in a Rabbit Heart Model of Torsade de Pointes: Low Torsadogenic Potential Despite QT Prolongation J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 64 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Haverkamp, L. Eckardt, G. Monnig, E. Schulze-Bahr, H. Wedekind, P. Kirchhof, F. Haverkamp, and G. Breithardt Clinical aspects of ventricular arrhythmias associated with QT prolongation Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K81 - K88. [Abstract] [PDF]
|
|
|
|
|
|
V. Rybalchenko, N. Prevarskaya, F. Van Coppenolle, G. Legrand, L. Lemonnier, X. Le Bourhis, and R. Skryma Verapamil Inhibits Proliferation of LNCaP Human Prostate Cancer Cells Influencing K+ Channel Gating Mol. Pharmacol., June 1, 2001; 59(6): 1376 - 1387. [Abstract] [Full Text]
|
|
|
|
|
|
S. Zhang, S. Rajamani, Y. Chen, Q. Gong, Y. Rong, Z. Zhou, A. Ruoho, and C. T. January Cocaine Blocks HERG, but Not KvLQT1+minK, Potassium Channels Mol. Pharmacol., April 16, 2001; 59(5): 1069 - 1076. [Abstract] [Full Text]
|
|
|
|
|
|
D. Thomas, G. Wendt-Nordahl, K. Röckl, E. Ficker, A. M. Brown, and J. Kiehn High-Affinity Blockade of Human Ether-A-Go-Go-Related Gene Human Cardiac Potassium Channels by the Novel Antiarrhythmic Drug BRL-32872 J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 753 - 761. [Abstract] [Full Text]
|
|
|
|
 |
|
 B.-R. Choi, T. Liu, and G. Salama The Distribution of Refractory Periods Influences the Dynamics of Ventricular Fibrillation Circ. Res., March 16, 2001; 88 (5): e49 - e58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fareh, A. Benardeau, and S. Nattel Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs Cardiovasc Res, March 1, 2001; 49(4): 762 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Grace and A.J. Camm Voltage-gated calcium-channels and antiarrhythmic drug action Cardiovasc Res, January 1, 2000; 45(1): 43 - 51. [Full Text] [PDF]
|
|
|
|
|
|
D. M Roden and J. R Balser A plethora of mechanisms in the HERG-related long QT syndrome: Genetics meets electrophysiology Cardiovasc Res, November 1, 1999; 44(2): 242 - 246. [Full Text] [PDF]
|
|